Cells: Hemostemix ACP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants
Hemostemix (OTCQB: HMTXF) has announced groundbreaking research published in Cells regarding how its ACP-01 and NCP-01 cell therapies could potentially improve brain-computer interface (BCI) longevity and performance.
The research demonstrates how these autologous blood-derived cell precursors could address key limitations of BCIs, which currently fail within 6 months to 1 year. ACP-01 produces signals that suppress inflammation and support blood vessel growth, while NCP-01 promotes neural plasticity and new synaptic connections.
The company sees potential for licensing opportunities with BCI technology companies to combine their stem-cell therapy with cutting-edge neural interfaces, aiming to extend implant longevity from months to potentially a lifetime while improving signal fidelity and learning capabilities.
Hemostemix (OTCQB: HMTXF) ha annunciato una ricerca innovativa pubblicata su Cells riguardo a come le sue terapie cellulari ACP-01 e NCP-01 potrebbero migliorare la durata e le prestazioni delle interfacce cervello-computer (BCI).
Lo studio dimostra come questi precursori cellulari autologhi derivati dal sangue possano superare le principali limitazioni delle BCI, che attualmente falliscono entro 6 mesi o un anno. ACP-01 produce segnali che sopprimono l'infiammazione e favoriscono la crescita dei vasi sanguigni, mentre NCP-01 stimola la plasticit脿 neurale e la formazione di nuove connessioni sinaptiche.
L'azienda intravede opportunit脿 di licenza con societ脿 tecnologiche nel campo delle BCI per combinare la sua terapia con cellule staminali con interfacce neurali all'avanguardia, con l'obiettivo di estendere la durata degli impianti da mesi a potenzialmente tutta la vita, migliorando al contempo la fedelt脿 del segnale e le capacit脿 di apprendimento.
Hemostemix (OTCQB: HMTXF) ha anunciado una investigaci贸n innovadora publicada en Cells sobre c贸mo sus terapias celulares ACP-01 y NCP-01 podr铆an mejorar la longevidad y el rendimiento de las interfaces cerebro-computadora (BCI).
La investigaci贸n demuestra c贸mo estos precursores celulares aut贸logos derivados de la sangre podr铆an superar las limitaciones clave de las BCI, que actualmente fallan entre 6 meses y 1 a帽o. ACP-01 genera se帽ales que suprimen la inflamaci贸n y apoyan el crecimiento de vasos sangu铆neos, mientras que NCP-01 promueve la plasticidad neural y nuevas conexiones sin谩pticas.
La compa帽铆a ve potencial para oportunidades de licenciamiento con empresas de tecnolog铆a BCI para combinar su terapia con c茅lulas madre con interfaces neuronales de vanguardia, con el objetivo de extender la longevidad del implante de meses a potencialmente toda la vida, mejorando la fidelidad de la se帽al y las capacidades de aprendizaje.
Hemostemix (OTCQB: HMTXF)電� 鞛愳偓鞚� ACP-01 氚� NCP-01 靹疙彫 旃橂鞝�臧� 雵�-旎错摠韯� 鞚疙劙韼橃澊鞀�(BCI)鞚� 靾橂獏瓿� 靹彪姤鞚� 頄レ儊鞁滍偓 靾� 鞛堧姅 氚╇矔鞐� 甏�頃� 須嶊赴鞝侅澑 鞐瓣惮 瓴瓣臣毳� Cells 鞝�雱愳棎 氚滍憸頄堨姷雼堧嫟.
鞚� 鞐瓣惮電� 鞛愱皜 順堨暋 鞙犽灅 靹疙彫 鞝勱惮觳�臧� 順勳灛 6臧滌洈鞐愳劀 1雲� 雮挫棎 鞁ろ尐頃橂姅 BCI鞚� 欤检殧 頃滉硠毳� 鞏措柣瓴� 攴闺车頃� 靾� 鞛堧姅歆� 氤挫棳欷嶋媹雼�. ACP-01鞚� 鞐检鞚� 鞏奠牅頃橁碃 順堦磤 靹膘灔鞚� 歆�鞗愴晿電� 鞁犿樃毳� 靸濎劚頃橂┌, NCP-01鞚� 鞁犼步 臧�靻岇劚瓿� 靸堧鞖� 鞁滊儏鞀� 鞐瓣舶鞚� 齑夓頃╇媹雼�.
须岇偓电� BCI 旮办垹 旮办梾瓿检潣 霛检澊靹犾姢 旮绊殞毳� 韱淀暣 欷勱赴靹疙彫 旃橂鞝滊ゼ 斓滌波雼� 鞁犼步 鞚疙劙韼橃澊鞀れ檧 瓴绊暕頃橃棳 鞚挫嫕氍检潣 靾橂獏鞚� 氇� 臧滌洈鞐愳劀 鞛犾灛鞝侅溂搿� 韽夓儩鞙茧 鞐办灔頃橁碃 鞁犿樃 鞝曧檿霃勳檧 頃欖姷 電ル牓鞚� 頄レ儊鞁滍偆電� 瓴冹潉 氇╉憸搿� 頃橁碃 鞛堨姷雼堧嫟.
Hemostemix (OTCQB : HMTXF) a annonc茅 une recherche r茅volutionnaire publi茅e dans Cells concernant la mani猫re dont ses th茅rapies cellulaires ACP-01 et NCP-01 pourraient potentiellement am茅liorer la long茅vit茅 et les performances des interfaces cerveau-ordinateur (BCI).
Cette recherche d茅montre comment ces pr茅curseurs cellulaires autologues d茅riv茅s du sang pourraient r茅soudre les principales limites des BCI, qui 茅chouent actuellement entre 6 mois et 1 an. ACP-01 produit des signaux qui suppriment l'inflammation et favorisent la croissance des vaisseaux sanguins, tandis que NCP-01 stimule la plasticit茅 neuronale et la formation de nouvelles connexions synaptiques.
L'entreprise entrevoit des opportunit茅s de licence avec des soci茅t茅s sp茅cialis茅es dans la technologie BCI afin de combiner leur th茅rapie par cellules souches avec des interfaces neuronales de pointe, visant 脿 prolonger la dur茅e de vie des implants de quelques mois 脿 potentiellement toute une vie, tout en am茅liorant la fid茅lit茅 des signaux et les capacit茅s d'apprentissage.
Hemostemix (OTCQB: HMTXF) hat bahnbrechende Forschungsergebnisse ver枚ffentlicht, die in Cells erschienen sind und zeigen, wie seine ACP-01 und NCP-01 Zelltherapien die Langlebigkeit und Leistung von Gehirn-Computer-Schnittstellen (BCI) verbessern k枚nnten.
Die Forschung zeigt, wie diese autologen, blutabgeleiteten Zellvorl盲ufer zentrale Einschr盲nkungen von BCIs 眉berwinden k枚nnten, die derzeit innerhalb von 6 Monaten bis zu einem Jahr ausfallen. ACP-01 erzeugt Signale, die Entz眉ndungen unterdr眉cken und das Wachstum von Blutgef盲脽en f枚rdern, w盲hrend NCP-01 die neuronale Plastizit盲t und neue synaptische Verbindungen unterst眉tzt.
Das Unternehmen sieht Potenzial f眉r Lizenzierungsm枚glichkeiten mit BCI-Technologieunternehmen, um ihre Stammzelltherapie mit modernsten neuronalen Schnittstellen zu kombinieren, mit dem Ziel, die Lebensdauer von Implantaten von Monaten auf potenziell ein ganzes Leben zu verl盲ngern und gleichzeitig die Signalgenauigkeit und Lernf盲higkeit zu verbessern.
- Scientific validation of ACP-01 and NCP-01's potential in BCI applications
- Opportunity for licensing partnerships with BCI technology companies
- Potential to solve major BCI limitations (longevity, signal fidelity)
- Company's technology could address a significant market need in neural interfaces
- Research is still theoretical with no clinical validation yet
- Timeline for potential commercialization not specified
- No financial metrics or market size estimates provided
Calgary, Alberta--(Newsfile Corp. - July 31, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to highlight a groundbreaking research article published in on June 29, 2025, by Fraser C. Henderson Sr. and Ms. Kelly Tuchman, exploring how a combination of the patient's own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term performance of brain-computer interfaces (BCIs).
Key Scientific Insights
The Challenge with BCIs: Inflammation, scarring, and programmed cell death undermine performance over time
Implantable electrodes within the brain have enabled remarkable achievements—e.g., paralyzed individuals playing chess and blind individuals recognizing letters. However, these devices often fail between six months and one year. The longest BCI in use lasted seven years. Even then, issues like inflammation, scarring, and programmed cell death (apoptosis) undermine performance over time.
Hemostemix's Innovative Cell-Based Solution
The article proposes using two types of autologous (patient-derived) progenitor cells: Angiogenic Cell Precursors (ACP-01, VesCell™) and Neural Cell Precursors (NCP-01), delivered into the cerebrospinal fluid, to foster a healing cellular environment around the implant.
ACP-01 (VesCell™) produces signals like IL-8, VEGF, and angiogenin. They attract natural killer (NK) cells that suppress inflammation, reduce tissue scarring, and support new blood vessel growth (angiogenesis).
ACP-01potentiate healing through the expression of tissue regeneration factors CXCL8, VEGF, and angiogenin. They include CD34+ (blood stem cell). CXCL8 recruit endogenous CD34+, that circulate peripherally, to the site of implant.
CXCL8 (interleukin-8) activate NF-κB, resulting in gene transcription and protein synthesis necessary for learning (memory formation and consolidation).
NCP- 01express receptors like CXCR4, and migrate toward the BCI site. NCP help shift immune cells into a neuroprotective (M2) state. NCP differentiate into neurons and supporting glial cells that promote new synaptic connections and neural plasticity.
Figure 1. Natural Killer (NK) cells recruited by angiogenic cell precursors (ACPs) suppress inflammation through the release of anti-inflammatory cytokines, dendritic cell and monocyte maturation, and lysis of auto-aggressive T cells. Created in BioRender. Tuchman, K. (2025)
To view an enhanced version of this graphic, please visit:
Figure 2. Angiogenic cell precursors (ACPs) potentiate healing through expression of tissue regeneration factors such as the chemokine interleukin-8 (CXCL8), vascular endothelial growth factor (VEGF) and angiogenin. In addition to the robust presence of CD34+ in ACPs, the expressed CXCL8 recruits peripheral CD34+ precursor cells, further supporting angiogenesis. Created by BioRender. Tuchman, K. (2025)
To view an enhanced version of this graphic, please visit:
Figure 3. Interleukin-8 (CXCL8) is expressed by angiogenic cell precursors (ACPs), and activates
the canonical NF-κB pathway, resulting in gene transcription and protein synthesis necessary for
memory formation and consolidation. Created in BioRender. Tuchman, K. (2025)
To view an enhanced version of this graphic, please visit:
Mechanism of Action
Together, ACP and NCP support a cascade of beneficial molecular events:
Activation of neurotrophic factors and NF-κB pathways that protect cells (anti-apoptosis).
Promotion of synaptogenesis (formation of connections between neurons), neuritogenesis (growth of neural processes), to improve learning-related plasticity.
As the patient's DNA-based engineered cellular environment, ACP and NCP home to the site of BCI, decrease inflammation, increase angiogenesis, increase neuro-protectiveness, promote new synaptic connections, and may dramatically extend both the lifespan of BCI, signal fidelity and learning.
Why This Matters to Hemostemix
Hemostemix's patented proprietary platform produces ACP-01 (angiogenic precursors) and NCP-01 (neural precursors) from a patient's own blood. This new research provides a scientific basis of how the combination of ACP-01+NCP-01 promises to overcome the major limitations in BCI implants.
- The findings align with Hemostemix's vision of licensing ACP-01 and NCP-01 to enhance BCI longevity and functionalities.
Forward-Looking Perspective
This research paves the way for:
Licensing with BCI technology companies to combine autologous stem-cell support of BCI with cutting-edge patient-based angiogenic and neural interfaces.
Rapid preclinical and clinical testing of ACP-01 + NCP-01 at BCI implant sites.
"We imagine a world where the environment for BCI, the patient's brain, augmented by the patients' own stem cells, improves the longevity of the implants from months to a lifetime, improves signal fidelity to increase functional movement, and increases learning and memory retention," stated Dr. Fraser Henderson, lead author.
"I want to thank Dr. Henderson and Ms. Tuchman for this very thorough exposition of the benefits of using one's own DNA structured as ACP & NCP to improve BCIs. Truly, this is incredible work. Coupled with our market analyses of the top three BCI companies, shareholders can expect more news to follow, as Mr. Lawrence, Chief Commercialization Officer and I meet with potential partners," stated Thomas Smeenk, CEO.
In Summary
Dr. Henderson has outlined a new cell-based approach that may allow brain implants to work reliably for years. By delivering two types of the patient's blood-derived stem cell precursors—one that fights inflammation and boosts blood flow, the other that helps build new neuronal cells—this method could protect and improve the brain at the site of BCI implant. Hemostemix's ready-to-use cell products (ACP-01 and NCP-01) are a direct fit for this approach and could potentially transform how long and well brain-computer interfaces function.
ABOUT HEMOSTEMIX
Founded in 2003, Hemostemix is a stem-cell therapeutics company with patented technology to generate autologous angiogenic and neural cell precursors from patient blood. Its ACP-01 and NCP-01 cell lines aim to treat cardiovascular, neurological, and implant-related conditions. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for , , , , , and . Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the . As compared to a five year mortality rate of
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: [email protected] / PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the publication in CELLS of the properties of ACP-01+NCP-01 and the improvement of brain computer interface (BCI) technologies. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at . Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit
FAQ
What is the potential impact of Hemostemix's ACP-01 and NCP-01 on brain-computer interfaces?
How do Hemostemix's (HMTXF) cell therapies work with brain-computer interfaces?
What are the current limitations of brain-computer interfaces that Hemostemix aims to solve?
What are the next steps for Hemostemix (HMTXF) in commercializing this technology?
How does Hemostemix's technology differ from current BCI solutions?
